Videos
Breaking Down the Positive Findings of Phase III Trial for Prostate Cancer Drug
06/01/2020
Mark Wildgust, PhD, vice president, medical affairs/oncology, Janssen, discusses the results of the SPARTAN study that examined use of Erleada (apalutamide) for the treatment of prostate cancer, and highlights how the findings of this study impacts the future of care.
Current Issue
October/November/December Volume 21, Issue 4, First Report Managed CareWhat's Trending?
Subscribe to our eNewsletters!
First Report Managed Care Newsletter